Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule Added to the Russell 2000® Index
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that it has been added to the Russell 2000 ® Index, a subset of the Russell 3000 ®  Index, effective as of market closing on June 22, 2018 , at the conclusion of the annual Russell US Index
View HTML
Toggle Summary ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 15, 2018-- ArQule, Inc. (Nasdaq:ARQL) today is presenting preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase
View HTML
Toggle Summary ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 14, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will present at The JMP Securities Life Sciences Conference on June 21,
View HTML
Toggle Summary ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA)
Data strengthens clinical profile and supports further dose escalation for ARQ 531 BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 7, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or
View HTML
Toggle Summary ArQule to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--May 31, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will present at the Jefferies 2018 Healthcare Conference on June 7, 2018 ,
View HTML
Toggle Summary ArQule Strengthens Executive Team with Two Key Appointments
Newly Created Positions of Senior Vice President, Corporate Strategy, Communication & Finance and Senior Vice President, Program Management and Product Planning BURLINGTON, Mass. --(BUSINESS WIRE)--May 24, 2018-- ArQule, Inc. (NASDAQ: ARQL) today announced two strategic additions to its executive
View HTML
Toggle Summary ArQule Reports First Quarter 2018 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)--May 7, 2018-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2018. For the quarter ended March 31, 2018 , the Company reported a net loss of $6,532,000 , or $0.07 per
View HTML
Toggle Summary ArQule to Report First Quarter 2018 Financial Results on May 7, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Apr. 23, 2018-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter of 2018 before the market opens on Monday, May 7, 2018 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China
ArQule eligible to receive up to $336 million including upfront, regulatory and commercial milestone payments ArQule to host investor conference call including transaction details, AACR highlights and an update on clinical strategy April 18, 2018 at 9:00 A.M. ET BURLINGTON, Mass.
View HTML
Toggle Summary ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Mar. 20, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will present at the 17 th Annual Needham Healthcare Conference on March
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.